Moreover, sensitivity of 27 commonly used DLBCL cell lines of ABC and GCB subtypes to MMAE-conjugated ADCs: anti-CD22 (pinatuzumab vedotin) and anti-CD79B ADCs (Pola) was assessed [96]. Here, CD79B is linked to diffuse large B-cell lymphoma.